-+ 0.00%
-+ 0.00%
-+ 0.00%

Liminatus Pharma amends InnocsAI merger terms, targets July 2 close

PUBT·06/30/2026 20:30:59
Listen to the news
Liminatus Pharma amends InnocsAI merger terms, targets July 2 close
  • Liminatus amended and restated its merger agreement with InnocsAI, restructuring terms to allow closing before stockholder approval.
  • Closing is expected on July 2, 2026, subject to customary closing conditions.
  • InnocsAI holders to receive Liminatus common stock and non-voting convertible preferred stock priced at USD 0.20 per share.
  • Implied transaction value about USD 320 million; includes contingent value rights for 20% of future net proceeds from certain strategic transactions.
  • Common stock portion capped at an estimated 19.99% of pre-closing shares; preferred converts only after stockholder approval.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606301630PRIMZONEFULLFEED9755007) on June 30, 2026, and is solely responsible for the information contained therein.